PT1150686E - Matriz directamente compressivel para libertacao controlada de doses diarias unitarias de claritromicina - Google Patents

Matriz directamente compressivel para libertacao controlada de doses diarias unitarias de claritromicina

Info

Publication number
PT1150686E
PT1150686E PT00905514T PT00905514T PT1150686E PT 1150686 E PT1150686 E PT 1150686E PT 00905514 T PT00905514 T PT 00905514T PT 00905514 T PT00905514 T PT 00905514T PT 1150686 E PT1150686 E PT 1150686E
Authority
PT
Portugal
Prior art keywords
clarithromycin
controlled release
matrix
daily dose
compressive
Prior art date
Application number
PT00905514T
Other languages
English (en)
Inventor
Ljubomira Barbara Rebic
Fercej Temeljotov Darja
Mohar Milojka
Salobir Mateja
Opresnik Marko
Original Assignee
Lek Farmacevtska Druzba Dd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lek Farmacevtska Druzba Dd filed Critical Lek Farmacevtska Druzba Dd
Publication of PT1150686E publication Critical patent/PT1150686E/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7048—Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin, digitoxin or digoxin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/286—Polysaccharides, e.g. gums; Cyclodextrin
    • A61K9/2866—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Molecular Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biophysics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
PT00905514T 1999-02-19 2000-02-17 Matriz directamente compressivel para libertacao controlada de doses diarias unitarias de claritromicina PT1150686E (pt)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
SI9900039A SI20150A (sl) 1999-02-19 1999-02-19 Direktno stisljivi matriks za nadzorovano sproščanje celodnevne doze klaritromicina

Publications (1)

Publication Number Publication Date
PT1150686E true PT1150686E (pt) 2005-05-31

Family

ID=20432410

Family Applications (1)

Application Number Title Priority Date Filing Date
PT00905514T PT1150686E (pt) 1999-02-19 2000-02-17 Matriz directamente compressivel para libertacao controlada de doses diarias unitarias de claritromicina

Country Status (21)

Country Link
EP (1) EP1150686B1 (pt)
AT (1) ATE286736T1 (pt)
AU (1) AU776912B2 (pt)
BG (1) BG65324B1 (pt)
CY (1) CY1107454T1 (pt)
CZ (1) CZ302781B6 (pt)
DE (1) DE60017361T2 (pt)
DK (1) DK1150686T3 (pt)
EE (1) EE05422B1 (pt)
ES (1) ES2235834T3 (pt)
HR (1) HRP20010684B1 (pt)
HU (1) HUP0105481A3 (pt)
PL (1) PL196665B1 (pt)
PT (1) PT1150686E (pt)
RS (1) RS50298B (pt)
RU (1) RU2237480C2 (pt)
SI (2) SI20150A (pt)
SK (1) SK287525B6 (pt)
TR (1) TR200102396T2 (pt)
UA (1) UA74778C2 (pt)
WO (1) WO2000048607A1 (pt)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TR200000054A2 (tr) * 2000-01-05 2001-08-21 Sanovel İlaç San. Ve Ti̇c. Anoni̇m Şi̇rketi̇ Klaritromisin içeren sürekli salım sağlayan tablet formülasyonları.
US6544555B2 (en) 2000-02-24 2003-04-08 Advancis Pharmaceutical Corp. Antibiotic product, use and formulation thereof
IN192748B (pt) * 2000-08-29 2004-05-15 Ranbaxy Lab Ltd
US20020068078A1 (en) 2000-10-13 2002-06-06 Rudnic Edward M. Antifungal product, use and formulation thereof
US6673369B2 (en) 2001-08-29 2004-01-06 Ranbaxy Laboratories Limited Controlled release formulation
US6642276B2 (en) * 2001-10-01 2003-11-04 M/S Ind-Swift Limited Controlled release macrolide pharmaceutical formulations
SE0103369D0 (sv) * 2001-10-09 2001-10-09 Astrazeneca Ab Pharmaceutical formulation
EP1443910A1 (en) 2001-11-02 2004-08-11 Wockhardt Limited Controlled release compositions for macrolide antimicrobial agents
CN1652753A (zh) * 2002-04-03 2005-08-10 兰贝克赛实验室有限公司 具有改进的生物利用度的克拉霉素制剂
US20060083759A1 (en) * 2002-07-17 2006-04-20 Aleksander Resman Stabilization of the profile of release of active substances from a formulation
EP1534238A1 (en) * 2002-07-29 2005-06-01 ALZA Corporation Formulations and dosage forms for controlled delivery of topiramate
US20050232995A1 (en) 2002-07-29 2005-10-20 Yam Nyomi V Methods and dosage forms for controlled delivery of paliperidone and risperidone
AU2004264356B2 (en) 2003-08-12 2011-01-27 Shionogi, Inc. Antibiotic product, use and formulation thereof
WO2005023221A1 (en) * 2003-09-05 2005-03-17 Ranbaxy Laboratories Limited Clarithromycin formulations having improved biovailability
US7943585B2 (en) * 2003-12-22 2011-05-17 Sandoz, Inc. Extended release antibiotic composition
EP1732518A1 (en) * 2004-03-24 2006-12-20 Lupin Ltd. Clarithromycin extended release formulation
EP2283824B1 (en) 2009-07-30 2017-04-19 Special Products Line S.p.A. Compositions and formulations based on swellable matrices for sustained release of poorly soluble drugs such as clarithromycin

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4331803A (en) * 1980-06-04 1982-05-25 Taisho Pharmaceutical Co., Ltd. Novel erythromycin compounds
JPS60163823A (ja) * 1984-02-03 1985-08-26 Taisho Pharmaceut Co Ltd 経口投与製剤
JPS60214796A (ja) * 1984-04-06 1985-10-28 Taisho Pharmaceut Co Ltd ６−０−メチルエリスロマイシン類の製法
JPS63188621A (ja) * 1987-01-30 1988-08-04 Taisho Pharmaceut Co Ltd 矯味経口製剤
US4808411A (en) * 1987-06-05 1989-02-28 Abbott Laboratories Antibiotic-polymer compositions
IL87219A0 (en) * 1987-08-07 1988-12-30 Abbott Lab Erythromycin formulations for oral administration
JP2553882B2 (ja) * 1987-08-08 1996-11-13 富士写真光機株式会社 走査結像光学系
US5599556A (en) * 1991-12-31 1997-02-04 Abbott Laboratories Prolamine coatings for taste masking
DE69530973T2 (de) * 1994-02-16 2004-05-19 Abbott Laboratories, Abbott Park Verfahren zur herstellung feinteiliger pharmazeutischer formulierungen

Also Published As

Publication number Publication date
EP1150686A1 (en) 2001-11-07
BG65324B1 (bg) 2008-02-29
DE60017361T2 (de) 2005-12-22
CZ20012964A3 (cs) 2002-01-16
DK1150686T3 (da) 2005-04-04
EP1150686B1 (en) 2005-01-12
HUP0105481A3 (en) 2003-04-28
SI1150686T1 (en) 2005-06-30
PL350419A1 (en) 2002-12-16
SK11972001A3 (sk) 2002-02-05
AU2704900A (en) 2000-09-04
HUP0105481A2 (hu) 2002-05-29
WO2000048607A1 (en) 2000-08-24
EE05422B1 (et) 2011-06-15
SK287525B6 (sk) 2011-01-04
HRP20010684B1 (en) 2011-01-31
RS50298B (sr) 2009-09-08
SI20150A (sl) 2000-08-31
TR200102396T2 (tr) 2002-01-21
YU59201A (sh) 2004-07-15
RU2237480C2 (ru) 2004-10-10
PL196665B1 (pl) 2008-01-31
AU776912B2 (en) 2004-09-23
CZ302781B6 (cs) 2011-11-02
BG105914A (bg) 2002-05-31
CY1107454T1 (el) 2012-12-19
DE60017361D1 (de) 2005-02-17
UA74778C2 (en) 2006-02-15
EE200100433A (et) 2002-12-16
ES2235834T3 (es) 2005-07-16
ATE286736T1 (de) 2005-01-15
HRP20010684A2 (en) 2002-10-31

Similar Documents

Publication Publication Date Title
PT1150686E (pt) Matriz directamente compressivel para libertacao controlada de doses diarias unitarias de claritromicina
NO20011721D0 (no) N-aralkylaminotetraliner som ligander for neuropeptid Y Y5 reseptor
ATE293995T1 (de) Pharmazeutische zusammensetzungen, die wirkstoffabsorptionsfördernde verbindungen enthalten
HN2000000267A (es) Oxazolidinonas substituidas y su uso
BR0309004A (pt) Matriz para liberação gradual, invariante e independente dos compostos ativos
MX9202407A (es) Composicion farmaceutica que contiene un compuesto de alilamina como el agente activo y proceso para su preparacion.
AU2002223684A1 (en) Combination comprising an agent decreasing vegf activity and an agent decreasing egf activity
CY1107819T1 (el) Φαρμακευτικη διαμορφωση της ολανζαπινης
BRPI0407181A (pt) Formulação farmacêutica
NO20045385L (no) Farmasoytisk preparat inneholdende okskarbazepin med kontrollert frigivelse av aktivt stoff
ECSP930933A (es) Composicion farmaceutica y procedimiento para prepararla
WO2005065639A3 (en) Novel pharmaceutical compositions
BR0107899A (pt) Processo para produzir uma preparação de ingrediente ativo compreendendo ibuprofeno, preparação de ingrediente ativo, uso da mesma, preparação farmacêutica, uso da mesma, processo para produzir formas de dosagem sólidas, e, forma de dosagem sólida
BR0212467A (pt) Procedimento de preparação dos ácidos hidróxigraxos insaturados e de seus ésteres, sua utilização em preparações farmacêuticas e/ou cosméticas
AU2001227030A1 (en) Pharmaceutical composition for controlled release of an active ingredient
ES2176786T3 (es) Uso de extractos de ginkgo biloba para la preparacion de composicionesfarmaceuticas.
CA2383140A1 (en) Ppar.alpha. and ppar.gamma. inhibitors
DK0521353T3 (da) Lægemiddel med antineoplastisk virkning, der som virksomt stof indeholder octadecyl-(2-(N-metylpiperidino)-ethyl)-phosphat og fremgangsmåde til fremstilling deraf
AR037543A1 (es) Metodo para la terapia del cancer y composicion farmaceutica
AR005730A1 (es) Forma de fanciclovir, procedimiento para prepararla, composiciones farmaceuticas que la contienen y metodo para el tratamiento o profilaxis deinfecciones virales y el uso de dicha forma -fanciclovir monoidrato.
BR0116570A (pt) Compostos de azol e seu uso como agentes antifúngicos
BR9710629A (pt) Composi-Æo farmac-utica processo para sua prepara-Æo composto para utiliza-Æo como agente terap-utico e utiliza-Æo e utiliza-Æo de um composto
BR0202759A (pt) Composição farmacêutica de liberação modificada contendo bupropiona como substância ativa
AR012019A1 (es) Compuesto de criptoficina y su uso para preparar un medicamento